PPARγ signaling and metabolism: the good, the bad and the future.
PPARγ signaling and metabolism: the good, the bad and the future.
复制标题
作者：
噻唑烷二酮类（TZD）是一种有效的胰岛素增敏剂，通过核受体过氧化物酶体增殖物激活受体-γ（PPARγ）发挥作用，是治疗2型糖尿病的高效口服药物。然而，它们独特的益处被液体潴留、体重增加、骨质流失和充血性心力衰竭的风险所掩盖。这就提出了一个问题，即是否有可能建立一个更安全的一代PPARγ特异性药物，引起更少的副作用，同时保持胰岛素增敏潜力。最近的研究支持了PPARγ通路的持续生理和治疗相关性，也为开发减少或消除不良反应的新型分子提供了机会。这篇综述强调了在能量稳态和代谢疾病中理解PPARγ信号的关键进展，并为与基于TZD的治疗相关的不良事件提供了新的解释。
Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral medications for type 2 diabetes. However, their unique benefits are shadowed by the risk for fluid retention, weight gain, bone loss and congestive heart failure. This raises the question as to whether it is possible to build a safer generation of PPARγ-specific drugs that evoke fewer side effects while preserving insulin-sensitizing potential. Recent studies that have supported the continuing physiologic and therapeutic relevance of the PPARγ pathway also provide opportunities to develop newer classes of molecules that reduce or eliminate adverse effects. This review highlights key advances in understanding PPARγ signaling in energy homeostasis and metabolic disease and also provides new explanations for adverse events linked to TZD-based therapy.
登录
查看更多内容
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
10.9
作者：
Ahmadian, Maryam;Duncan, Robin E.;Sul, Hei Sook
通讯作者：
Sul, Hei Sook
影响因子：
15.9
作者：
Burant, CF;Sreenan, S;Graves, RA
通讯作者：
Graves, RA
影响因子：
8
作者：
Chappuis, Bernard;Braun, Monika;Christ, Emanuel R.
通讯作者：
Christ, Emanuel R.
DOI：
10.1152/ajprenal.00306.2011
发表时间：
2012-03-01
影响因子：
4.2
作者：
Borsting, Emily;Cheng, Vicki Pei-Chun;Cunard, Robyn
通讯作者：
Cunard, Robyn